Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combined antegrade femoral artery and retrograde popliteal artery recanalization for chronic occlusions of the superficial femoral artery.

Journal of vascular and interventional radiology : JVIR·2014
Same author

Stratified polymer brushes from microcontact printing of polydopamine initiator on polymer brush surfaces.

Macromolecular rapid communications·2014
Same author

Distinct morphological features of ruptured culprit plaque for acute coronary events compared to those with silent rupture and thin-cap fibroatheroma: a combined optical coherence tomography and intravascular ultrasound study.

Journal of the American College of Cardiology·2014
Same author

The ABI4-induced Arabidopsis ANAC060 transcription factor attenuates ABA signaling and renders seedlings sugar insensitive when present in the nucleus.

PLoS genetics·2014
Same author

Evaluation of global longitudinal strain of left ventricle and regional longitudinal strain in the region of left ventricular leads predicts the response to cardiac resynchronization therapy in patients with ischemic heart failure.

Cell biochemistry and biophysics·2014
Same author

Exosomes derived from mesenchymal stem cells.

International journal of molecular sciences·2014

Related Experiment Video

Updated: May 20, 2026

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
09:53

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Published on: January 10, 2025

Trimetazidine improves right ventricular function by increasing miR-21 expression.

Fang Liu1, Li Yin, Lulu Zhang

  • 1Key Laboratories of Education Ministry for Myocardial Ischemia Mechanism and Treatment, Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, PR China.

International Journal of Molecular Medicine
|July 31, 2012
PubMed
Summary

Trimetazidine (TMZ) protects right ventricular myocardial cells (RVMCs) from apoptosis by increasing microRNA-21 (miR-21) expression. This drug improves right heart function and reduces fibrosis in heart failure models.

More Related Videos

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
09:40

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice

Published on: May 13, 2019

Related Experiment Videos

Last Updated: May 20, 2026

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
09:53

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Published on: January 10, 2025

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
09:40

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice

Published on: May 13, 2019

Area of Science:

  • Cardiology
  • Molecular Biology
  • Pharmacology

Background:

  • Trimetazidine (TMZ) is known to improve left ventricular function and alleviate angina.
  • The non-metabolic effects and molecular actions of TMZ, particularly on the right ventricle, remain largely unelucidated.
  • Apoptosis in right ventricular myocardial cells (RVMCs) is a critical factor in right heart dysfunction.

Purpose of the Study:

  • To investigate the effects of Trimetazidine (TMZ) on right ventricular (RV) function and RV myocardial cell (RVMC) apoptosis.
  • To determine if TMZ regulates microRNA-21 (miR-21) expression in RVMCs.
  • To explore the potential of TMZ as a therapeutic agent for right heart failure.

Main Methods:

  • Cultured RVMCs and LV myocardial cells (LVMCs) were subjected to hypoxic stimulation.
  • Apoptosis was assessed using TUNEL staining and caspase-3 assays.
  • TMZ was administered to RVMCs and an in vivo model of right heart failure (hypoxia + Su5416) was used to evaluate therapeutic effects.

Main Results:

  • RVMCs exhibited more severe apoptosis and a greater decrease in miR-21 expression compared to LVMCs under hypoxia.
  • TMZ treatment significantly reduced apoptosis in RVMCs and increased miR-21 expression.
  • In vivo, TMZ improved RV function, reduced fibrosis, and protected RVMCs against apoptosis, correlating with increased miR-21 levels.

Conclusions:

  • Trimetazidine (TMZ) demonstrates protective effects against apoptosis in right ventricular myocardial cells (RVMCs).
  • The cardioprotective mechanism of TMZ involves the upregulation of microRNA-21 (miR-21) expression.
  • TMZ holds potential for improving right ventricular function and treating right heart failure.